MGMT and glioblastoma: Moreover, compared with 6 cycles of TMZ treatment, although extended TMZ chemotherapy did not obviously improve the PFS in newly diagnosed GBM patients with unmethylated MGMT promoter (mPFS: 10.55 months vs. 8.70 months, HR = 1.56, 95% CI: 0.87 ~ 2.82, P = 0.113), their OS was remarkably prolonged (mOS: 17.85 months vs. 14.80 months, HR = 1.90, 95% CI: 1.03 ~ 3.52, P = 0.028) (Figure 3).